Molecular Imaging: Page 74

PET reveals visual brain pattern of long COVID

By Will Morton

Nuclear medicine physicians in France have identified a metabolic pattern on brain PET images that indicates the presence of long COVID-19 in patients, according to a study published March 23 in the European Journal of Nuclear Medicine and Molecular Imaging.

March 24, 2022

PET improves prostate cancer survival predictions

By Will Morton

Prostate cancer PET scans can help predict how long patients may survive disease-free after radical prostatectomy, according to a study published March 17 in the European Journal of Nuclear Medicine and Molecular Imaging.

March 24, 2022

Clarity launching trial for prostate cancer therapy

By AuntMinnie.com staff writers

Clarity Pharmaceuticals is launching an investigator-initiated trial that will focus on the use of its copper-64 (Cu-64)-labeled radiopharmaceutical, Cu-64 SAR-bisPSMA, in prostate cancer.

March 23, 2022

FDA approves Lu-177 PSMA-617 for prostate cancer treatment

By Will Morton

The U.S. Food and Drug Administration (FDA) has approved lutetium-177 (Lu-177) prostate-specific membrane antigen radioligand therapy for the treatment of patients with metastatic prostate cancer.

March 22, 2022

Eckert & Ziegler partners with Alpha-9 Theranostics

By AuntMinnie.com staff writers

Isotope technology firm Eckert & Ziegler has agreed to supply lutetium-177 to the Canadian biotechnology firm Alpha-9 Theranostics for use in clinical trials.

March 22, 2022

Navidea reports revenue declines in Q4, all of 2021

By AuntMinnie.com staff writers

Radiopharmaceutical developer Navidea Biopharmaceuticals reported a decline in revenues for the fourth quarter of 2021 and the entire year.

March 22, 2022

Sysmex, Eisai highlight Alzheimer's research at AD/PD 2022

By AuntMinnie.com staff writers

Sysmex and Eisai shared research from their joint effort to create a diagnostic blood test for Alzheimer's disease at this week's International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2022) in Barcelona, Spain.

March 22, 2022

MedTrace Pharma prepares phase III trial for O-15 PET

By AuntMinnie.com staff writers

Danish PET technology developer MedTrace Pharma has received an investigational new drug exemption from the U.S. Food and Drug Administration, paving the way for a clinical trial to assess the firm's radioactive water (oxygen-15 water) PET imaging technique in detecting coronary artery disease.

March 21, 2022

ITM secures new investment to spur development

By AuntMinnie.com staff writers

German radiopharmaceutical firm ITM Isotope Technologies Munich has raised 33 million euros ($36.4 million U.S.) in another new equity investment.

March 21, 2022

NaF-PET reveals aortic wall injuries

By Will Morton

PET imaging with F-18 sodium fluoride (NaF) can detect activity related to tears in the outer wall of the aorta and could help manage patients with acute aortic syndrome, according to a study published March 16 in JACC: Cardiovascular Imaging.

March 21, 2022

Voxel-based technique improves tau PET for Alzheimer's disease

By Will Morton

A new technique that tracks individual voxels on tau PET scans in patients with Alzheimer's disease appears effective for detecting early signs of the disease, according to a study published March 17 in the Journal of Nuclear Medicine.

March 20, 2022

FluoGuide gives details on brain cancer research in Denmark

By AuntMinnie.com staff writers

FluoGuide said a research grant connected to its work with Rigshospitalet in Copenhagen, Denmark, will help it set up a phase II trial for the company's FG001 radiopharmaceutical candidate in patients with less aggressive brain cancers.

March 17, 2022

Previous Page

Page 74 of 614

Next Page